Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia in the U.S. population, accounting for more than one-third of leukemia cases among U.S. adults. The clinical course of this non-Hodgkin lymphoma subtype varies patient by patient, with some having a highly aggressive disease course and others having indolent disease that progresses slowly over several years and does not require immediate treatment.
The standard first-line treatment of CLL/SLL typically consists of chemoimmunotherapy, but the introduction of targeted therapies, such as the first-generation Bruton tyrosine kinase (BTK) inhibitor ibrutinib and the second-generation BTK inhibitor acalabrutinib, have reshaped the treatment paradigm for CLL/SLL, leading to improved patient outcomes and acceptable toxicity. Recent research has also shown that first-line treatment with ibrutinib leads to longer time to next treatment, compared with first-line chemoimmunotherapy or later administration of ibrutinib.
As the population grows and the number of people living with CLL/SLL in the U.S. increases, the economic burden and health care resource use associated with CLL therapy will continue to evolve. In this roundtable discussion, experts will discuss the state of CLL/SLL treatment in the United States, the role of BTK inhibitors and targeted therapies, and the financial implications of CLL treatment decisions.
Roundtable Reviews Costs, Value of Oral BTK Inhibitors in CLL/SLL
This roundtable discussion focused on the RESONATE-2 study, a randomized, multicenter, open-label, Phase 3 study which assessed the safety and efficacy of ibrutinib versus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia (CLL).
- James T. Kenney, RPH, MBA
Founder and President
- Catherine Coombs, MD
Assistant Professor of Medicine, Division of Hematology
The University of North Carolina Cancer Center
- Kate Taucher, PharmD, MHA, BCOP
System Manager, Oncology & Infusion Pharmacy Services
Video 1: Panel Introductions & Background on CLL
Video 2: A Breakdown of RESONATE-2
Video 3: The Importance of the Managed Care Professional in Dispensing Oncology Treatments & Closing Thoughts
This program was sponsored by Pharmacyclics. The views and opinions expressed in this program are those of the participants and speakers and may not reflect the views of AMCP and/or Pharmacyclics. The participants in this program have been compensated by Pharmacyclics for their participation.